Seattle Genetics (SGEN +3.1%) shares spike after confirming FDA approval of its Adcetris...

|About: Seattle Genetics, Inc. (SGEN)|By:, SA News Editor

Seattle Genetics (SGEN +3.1%) shares spike after confirming FDA approval of its Adcetris lymphoma drug and establishing a program offering access to reimbursement support, benefit investigations and patient assistance related to the drug.